Home › Clinical Trials › Cancer Clinical Trial › Colon Rectum
COVID-19 vaccine and protecting your health ›

Colon Rectum

Viewing Page 3 of 20 | Showing results 21 - 30 of 194

(WIRB) A Single Arm, Open-Label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer who Do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation

Krishnansu Tewari
Open

(WIRB) An open-label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator's choice chemotherapy in recurrent or metastatic platinum-refractory cervical carcinoma

Krishnansu Tewari
Open

(WIRB) Phase III Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

Krishnansu Tewari
Open

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

Natasha Mesinkovska, MD, PhD

UC Irvine Main Campus

A 36 month, Multicenter, Randomized, Phase 3, Double-blind, Placebo-Controlled, Study to Assess the Effect of isradipine on Patients with early Parkinson’s disease (PD) symptoms.

Neal Hermanowicz, MD

UC Irvine

A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY) (AIN457A2326)

Natasha Mesinkovska, MD, PhD

UC Irvine Dermatology Clinical Research Center, 1001 Hewitt Hall, Irvine, CA 92697

A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Lauren C Pinter-Brown
Open

A Clinical and Imaging Study to Evaluate a Novel Dentifrice

Petra Wilder-Smith, DDS, PhD

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III (Paces)

Jason Zell
Open

A Humanitarian Device Exemption Use Protocol of TheraSphere® HUD For Treatment of Unresectable Primary or Secondary Liver Cancer

Nadine Abi-Jaoudeh
Open